APR - 6 1998 C NETHE UNITED STATES PATENT AND TRADEMARK OFFICE

>) Attorney Docket) 6221/69666) MON-103.0

Art Group: 1809

Filed: September 19, 1997

For: AN IMMUNOLOGICAL PROCESS AND
CONSTRUCTS FOR INCREASING THE HDL
CHOLESTEROL CONCENTRATION BY
DNA VACCINATION

08/934,367

Needleman et al.

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicant:

Serial No.:

Pursuant to 37 C.F.R. §1.97, a list of documents is disclosed on the attached Form PTO-14449 that may be material to the examination of this application.

Documents A1-A47 are patents and published papers that are cited, discussed, and provided in the parental applications, U.S. Patent Application No. 08/785,997, filed on January 21, 1997 and U.S. Patent Application No. 08/788,882, filed January 21, 1997, of which this application is a Continuation-in-Part. Pursuant to 37 C.F.R. 1.98(d), it is understood that only a list of art is required inasmuch as the listed art has been provided and discussed previously.

Listed Documents B1-B29 are additional patents, patent applications, published papers and a SBIR that are cited and discussed in the current application, or have been subsequently located and thought to be relevant.

Documents for which the supplied date of publication lists the year of publication without the month were published sufficiently earlier than the effective U.S. filing date and any foreign priority date, so that the particular month of publication is not in issue. However, the availability date of the SBIR is unknown. Pursuant to §609 of the MPEP, it is understood that the month of publication is not required when the particular month of publication is not in issue.

No inferences should be drawn that the attached list represents a comprehensive investigation, or that any material disclosed is equivalent to the subject invention. In addition, none of the documents that have publication dates prior to the priority date of the above application anticipate the invention in this application.

The cited documents disclose numerous specific features. There has been no attempt to list each and every feature disclosed by each document. The Examiner is requested to review the documents and determine the extent of the

materiality of the document disclosures with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Also, there is reserved the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

Edward P. Gamson, Reg. No.29,381



Enclosures:

Form PTO-1449 Bound Volume of Art

Welsh & Katz, Ltd. 22nd Floor 120 South Riverside Plaza Chicago, Illinois 60606 312/655-1500

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, together with the stated enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 3, 1998.

Sheet 1 of 3 Serial No. U.S. Department of Commerce Atty. Docket No. (Rev. 5/92) 6221/69666 08/934,367 Patent and Trademark Office Comparable to MON-103.0 Form PTO-1449 **Applicants** ATION DISCLOSURE CITATION Needleman, et al. execute heets if necessary) Filing Date September 19, 1997 1809 U.S. PATENT DOCUMENTS Filing Date *Examiner Class Subclass If Appropriate Name Initial Document Number Date 530 324 4,767,842 08/30/88 Stevens A1 4,818,527 04/04/89 Thornton et al. 424 88 **A2** 5,582,997 12/10/96 Blondelle et al. 435 7.1 **A3** 435 68 4,710,463 12/1/87 Murray A4 435 7 07/17/90 Moriarty ÄŚ 4,942,125 514 ...45 09/03/85 Goodman et al. **A6** 4,539,205 45 02/17/87 Goodman et al. 514 4,643,992 A7 04/30/91 Goodman et al. 514 45 **A8** 5,011,828 45 Α9 5,093,318 03/03/92 Goodman et al. 514 514 12/03/96 5,580,859 Felgner et al. FOREIGN PATENT DOCUMENTS Translation No Class Yes Subclass Date Country **Document Number** 775 14 11/07/96 PCT **B2** WO 96/34888 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Lagrost, Biochem. Biophys. Acta, 1215:209-236 (1994) A10 Melchior, et al., Trends in Card. Med., 5:83-87 (1995) A11 A12 Drayna, et al., Nature, 327:632-634 (1987) Nagashima, et al., J. Lipid Res., 29:1643-1649 (1988) A13 Pape, et al., Atherosclerosis and Thrombosis, 11:1759-1771 (1991) A14 Gaynor, et al., Atherosclerosis, 110(1):101-109 (1994) A15 Melchior, et al., J. Biol. Chem., 270(36):21068-21074(1995) A16 Sugano, et al., J. Biol. Chem., 271(32):19080-19083 (1996) A17 A18 Hesler, et al., J. Biol. Chem., 263(11):5020-5023 (1988) Swenson, et al., J. Biol. Chem., 264(24):14318-14326(1989) A19 Tall, J. Lipid Res., 34:1255-1274 (1993) A20 A21 Whitlock, et al., J. Clin. Invest., 84:129-137 (1989) Evans, et al., J. Lipid Res., 35:1634-1645 (1994) A22 Date Considered Examiner

*Examiner:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Rev. 5/92) Comparable to Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 6221/69666 MON-103.0 Serial No. 08/934,367

Applicant

īN	FOR	ASION DISCLOSURE CITATION	Applicant Needleman, et al.		
		e selfsal sheets if necessary)	Filing Date September 19, 1997	Group 1809	
:		OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pag	es, Etc.)	
	A23 Zuckerman, et al., <i>Lipids</i> , <u>30</u> :307-311 (1995)				
	A24	Yoon, et al., Mol. Cells, 5(2):107-113 (1995)			
	A25	Jang, et al., J. Biochem. Mol. Biol., 28(3):216-220 (1995)			
	A26	Jeong, et al., Mol. Cells, 4(4):529-533 (1994)			
	A27	Tam, et al., Proc. Natl. Acad. Sci., USA, 86:9084-9088 (1989) Butz, et al., Peptide Research., 7(1):20-23			
	A28				
. =	A29	Kitagawa, et al., J. Biochem., 79:233 (1976)			
	A30-	Lachmann, et al., in 1986 Synthetic Peptides as An (1986)	tigens, Wiley, Chichester, (Ciba	Foundation Symposium 119) pages 25-40	
	A31	Connolly, et al., Biochem. J., 320:39-47 (1996)			
	A32	Moriarty, et al., Vaccines 90, Brown, et al. eds., C	Cold Spring Harbor Laboratory Pr	ress, Cold Spring Harbor, NY, 225-229 (1990)	
2	A33	Schödel, et al., Vaccines 90, Brown, et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 193-198 (1990)			
	A34	Hessler, et al., J. Biol. Chem., 263(11):5020-5023 (1988)			
	A35	Wang, et al., J. Biol. Chem., 267(25):17487-17490(1992)			
	A36	Schödel, et al., J. Virol., 66(1):106-114 (1992)			
	A37	Birnbaum, et al., J. Virol., 64(7):3319-3330 (1990)			
	A38	Schödel, et al., J. Exp. Med., 180:1037-1046 (1994)			
	A39	Schödel, et al., Vaccines 91, Brown, et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 319-325 (1991)			
	A40	Clarke, et al., Vacines 91, Brown, et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 313-318 (1991)			
	A41	Milich, et al., Vaccines 86, Brown, et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 377-382 (1986)			
	A42	Posnett, et al., J. Biol. Chem., 263:1719-1725 (1988)			
	A43				
	A44	Wang, et al., J. Biol. Chem., 270:612-618 (1995)			
	A45	Luckow, "Insect Cell Expression Technology", Protein Engineering: Principles and Practice, Cleland, et al., eds., Wiley-Liss, Inc., 183-218 (1996)			
	A46	Luckow, et al., J. Virol., <u>67</u> :4566-4579, (1993)			
	A47	Hippenmeyer, et al., Bio/Technology, 11:1037-1041 (1993)			
	В3	Kotake et al., J. Lipid Res., 37:599-605 (1996)			
	B4	Kotake et al., Biochem. Biophys. Acta, 1347:69-74 (1997)			
	B5	National Cholesterol Education Program Expert Panel in Detection, Evaluation and Treatment of High Blood Cholesterol in Adults J. Am. Med. Assoc., 269:3015-3023 (1993)			
Examiner			Date Considered		

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No. Serial No. (Rev. 5/92) U.S. Department of Commerce Patent and Trademark Office 6221/69666 08/934.367 Comparable to APR - 6 1998 Form PTO-1449 MON-103.0 Applicant COMPSOE OSURE CITATION Needleman, et al. (Use several sheets if necessary) Filing Date Group September 19, 1997 1809 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **B6** Gould et al., Circulation, 91:2274-2282 (1995) **B7** Manninen et al., Circulation, 85:37-45 (1992) Gordon et al., Circulation, 79:8-15 (1989) **B9** Lee et al., J. Biochem. Mol. Biol., 28(3):243-248 (1995) Bisgaier et al., Lipids, 811-818 (1994) B10 Coval et al., Bioorganic & Med. Chem. Lett., 5:605-619 (1995) -B11 **B12** McDonnell et al., N. Engl. J. Med., 334(1):42045 (1996). B13 Ulmer et al., Science, 259:1745-1749 (1993) **B14** Ulmer et al., ASM News, 62(9):476-479 (1996) **B15** Dixon, Bio/Technology, 13(5):420 (1995) **B**16 Fynan et al., Proc. Natl. Acad. Sci. U.S.A., 90:11478-11482 (1993) **B17** Matteucci et al., J. Am. Chem. Soc., 103:3185-3191 (1981) **B18** Davis et al., Biotechniques, 21:92-99 (1996) **B19** Green et al., Biopharm, 10(5):52-62 (1997) **B20** Marquet et al., Biopharm, 10(5):42-50 (1997) Wicks et al., Hum. Gene Ther., 6:317-323 (1995) B21 **B22** Mosemann, J. Immunol. Meth., 65:55-63 (1983) **B23** Schorr et al., Gene Ther., 1:S7 (1994) **B24** Coney et al., Vaccine, 12:1545-1550 (1994) **B25** Glenn et al., Methods in Enzymology, 263:339-350 (1996) **B26** Dawson et al., J. Biol. Chem., 264:16798-16803 (1989) **B27** Wolff et al., Science, 247:1465-1468 (1990) **B28** Heim et al., Nature, 373:663-664 (1995) **B29** SBIR Grant #1 R43 HL57045-01A1, July, 1996

Examiner

Date Considered

*Examiner:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



In Patent Application Serial No. 08/934,367 Needleman et al.

EPG/ag MON-103.0 (6221/69666)

Filed: September 19, 1997 Mailed: April 3, 1998
Title: AN IMMUNOLOGICAL PROCESS AND CONSTRUCTS FOR INCREASING
THE HDL CHOLESTEROL CONCENTRATION BY DNA VACCINATION

Information Disclosure Statement and Cert. of Mailing (4pgs), Form PTO-1449 (3pgs) and Bound Volume of art (B1-B29).

€.

ASSISTANT COMMISSIONER FOR PATENTS:

Please acknowledge-receipt of the above-identified documents by applying the Patent and Trademark Office receipt hereto and mailing this card.

Respectfully, Welsh & Katz, Ltd.